IMPRESS-Norway started inclusion of patients 1. April 2021 and at the end of January 2022 50 patients have been offered treatment in a IMPRESS-Norway cohort and over 170 patients have been analyzed in National Molecular Tumor Board meetings.
Menu
Personvern og informasjonskapsler
IMPRESS-Norway © 2021. Alle rettigheter forbeholdes.
Se tilgjengelighetserklæring for hjemmesiden til IMPRESS her